SSEP Update  
(Sweet Success Extension Program)  

JOIN us in Anaheim, CA for  
A Sweet Success Express Conference:  
Motivate to Prevent  
November 2-4, 2017  

Course Description: Motivate to Prevent  
SSEP envisions a health-oriented society in which evidenced-based management interventions and policies are continuously applied to improve the short and longterm health and well-being for women with diabetes during pregnancy and their off spring. We are excited to host this conference which provides a unique opportunity to advance this vision. 

Expert speakers will present a method for motivating change as well as evidence-based preventive interventions across the life stages, particularly in high risk demographics. The interventions target women at highest risk to develop diabetes during pregnancy or later in life, particularly indigenous populations, culturally and linguistically diverse communities and economically disadvantaged groups. National and International speakers will address current published and unpublished research, address controversial topics in keeping with the program theme, and provide Poster Presentations. The program will address concepts of prevention, intervention, self-management education and treatment modalities. The expanded specialty field of diabetes and reproductive health includes the future health of both mothers and offspring, which extends beyond birth for both mother and child. We work with provider groups to increase their knowledge and delivery of care by:  
• Developing and/or endorsing events and activities that increase their knowledge.  
• Supporting multidisciplinary health care teams as they take a proactive approach, focused on healthy lifestyles.  
• Encouraging providers to involve the entire health care system, community and patient at all levels in supporting lifestyle changes that foster improved long-term health and quality of life.  

SSEP Mission: Our mission is to improve pregnancy outcomes and long-term quality of life for women with diabetes and their offspring, which extends beyond birth for both mother and child. We work with provider groups to increase their knowledge and delivery of care by:  
• Developing and/or endorsing events and activities that increase their knowledge.  
• Supporting multidisciplinary health care teams as they take a proactive approach, focused on healthy lifestyles.  
• Encouraging providers to involve the entire health care system, community and patient at all levels in supporting lifestyle changes that foster improved long-term health and quality of life.  

Advisory Council  
Kristi Anderson, MD  
NM  
Lisa Bolman, RNC, CNM, CPHQ  
CA  
Zane Brown, MD  
WA  
Sharmila Chatterjee, Msc, MS, RD, CDE  
IL  
Jenny Chee, Certified Lactation Consultant  
AZ  
Julie Daley, RN, MS, CDE (RI)  
Co-Secretary  
Co-Secretary  
M. Joann Henry, RNC, MSHS  
Treasurer  
Treasurer  
Liz Miller, RN, BSN, MS, CDE (TX)  
RN Consultant  
RN Consultant  
Ramona Patterson, BSN, RN, CBC  
RN Consultant  
RN Consultant  
Geetha Rao, MS, RD, CDE (CA)  
RD Consultant  
RD Consultant  
Lisa Jim, RN  
AZ  
Siri Kjos, RN, BSN, MS, CDE  
TX  
Tina Jones, MS, RD, CDE  
OR  
Liz Miller, RN, BSN, MS, CDE  
WA  
Barbara Murphy, RN, MSN, CDE  
WA  
Katherine O’Connell, RN, RN  
(AZ)  
AZ  
(AZ)  
AZ  
(AZ)  
AZ  
(Gladys/Sandy) Ramos, MD  
CA  
Sandy Sinnes, RN, BSN, CDE  
WA  
Shelly Thorkelson, MSN, RN CNM, CDE  
NM  

goodness!
Smiling!  

SSEP Mailing Address/Phone:  PO Box 7447, Chico CA 95927-7447  -  Phone: 800.732.2387  

In this issue:  
Lipo Hypertrophy & 
ACOG Practice Bulletin: GDM  
See Page 2 and page 4  

Help SSEP when you shop on Amazon  
Just do your normal shopping starting at  
smile.amazon.com click on supporting (under the search bar) and choose SSEP  
Amazon donates 0.05% of purchase to SSEP!
Lipohypertrophy (or “lipo”) is a common complication of diabetes injections. It typically appears as a thickened, rubbery swelling of the tissue into which insulin or other diabetes medications were injected. It can vary significantly in texture from soft to firm, and in the amount of area affected.

**Risk Factors:**
There are several factors which increase the risk for lipohypertrophy. These include the duration of insulin therapy (p < 0.001), the presence of an incorrect injection technique or lack of site rotation (p < 0.001) and needle re-use (p = 0.02) (Frid, Kreugel, Grassi, et al, 2016). It also appears to occur more often in people taking a greater number of daily injections and in those using insulin pumps.

**Suspecting Lipohypertrophy**

**Clinical Implications:**
Lipohypertrophy has significant clinical implications, including:

- Erratic insulin absorption. In a euglycemic clamp study of 13 people with type 1 diabetes which compared insulin injections into lipohypertrophied versus normal tissue, they found a 34% reduction in insulin absorption when injecting into lipohypertrophied tissue (p < 0.002) (Famulia, et al, 2016). In concrete terms, this means that if the patient injected 10 units of insulin, they would only receive the benefit of 6.6 units!

- Postprandial glucose levels were 26% higher when insulin was injected into lipo (p < 0.05).

- 0.55% higher A1cs were found with those injecting in lipo (Frid, 2016).

- 10.1 to 15.0 units higher insulin use (Blanco, 2013; Frid, 2016). This also translates into higher insulin copays and costs.

- More frequent diabetic ketoacidosis (Frid, 2016).

- 42% higher rates of glycemic variability (2017) – [https://www.diabetes.co.uk/conditions/]

- 33% higher rates of unexplained hypoglycemia (Blanco, 2013). This last clinical implication is one with serious consequences and one which could be avoided by only injecting into healthy tissue. If the person with diabetes is experiencing a 34% reduction in insulin absorption, and they subsequently increase their insulin doses and then one day inject into “virgin” territory, hypoglycemia is very likely.

**Detecting Lipohypertrophy**

**Assessing for lipohypertrophy:**

Explain to your patient the importance of assessing their injection sites for lipo and how the presence of lipo could impact their diabetes management. Before you begin, obtain the patient’s permission to examine their injection sites. Some patients may feel embarrassed by the presence of lipo and I have personally had many patients who have described this as “my fat” and not understood that this was a result of years of injecting insulin into the same sites. Explain what you are looking for and obviously, always maintain the patient’s privacy. There are two parts to a complete lipo assessment: visual inspection and palpation. You want to visually inspect all injection sites, even those used less commonly. Directional lighting can help illuminate the lipohypertrophied tissue. You are looking for visible bumps, lumps, or indentations. The skin itself may appear pigmented, shiny or even textured. After doing a thorough visual inspection, spread ultrasound gel on the area to facilitate the exam. It may be easier to identify lipo by having the patient in different positions, both lying down and sitting. Ask the patient to relax her muscles. If you are examining the abdomen, it is best to have the patient lie on an exam table. Use two fingers (middle and index) and sweep around the injection site. I typically find using three fingers including my ring finger makes the exam easier for me but I have small hands. Use firm downward pressure pushing into the fat layer. You want to feel the difference in tissue structures. You can usually feel the edge of the lipo as a harder ridge. Define the total area in shape, size and texture. Describe the border of the lipo and normal tissue. It is important to quantify the area of lipo.

**Our responsibility:**
As a health care provider/educator, how often do you look at your patients’ injection sites? For women with gestational diabetes (GDM), this is unlikely to be a significant problem. But, please remember these women are at significantly increased risk for the development of type 2 diabetes in the five to ten years following their pregnancy with GDM and so need to be educated on the incidence of lipohypertrophy and how to avoid it. Blanco and colleagues (2013) identified that nearly two thirds (64.4%) of the 430 out-patient using insulin in their study as having lipohypertrophy. For women with either type 1 or type 2 diabetes preceding pregnancy, lipohypertrophy is something that must be suspected and then carefully assessed to determine if it is present.

**Definition:**
Lipohypertrophy is a common complication of diabetes injections. It typically appears as a thickened, rubbery swelling of the tissue into which insulin or other diabetes medications were injected. It can vary significantly in texture from soft to firm, and in the amount of area affected.

**Our Responsibility as Health Care Providers**

Donna L. Jornsay, MS, BSN, CPNP, CDE, CDTC, BC-ADM
Continued from Page 2

the distance from the longest diameter and record this in the
patient’s chart. The BD Lipo Assessment tool will also
include a skin-safe pen to mark off the area to be measured,
and an individual packet of ultrasound gel to facilitate your
palpation exam.

BD has also developed a Keeping Track of Your
Lipohypertrophy patient booklet to help patients track their
lipo and identify healthy injection sites. Also the BD new
Getting Started-Take Home Kit includes a helpful injection
grid for the abdomen.

PROTECTING AGAINST THE DEVELOPMENT OR
PROGRESSION OF LIPO

Protect patients who have lipo:

Once we have detected lipo, we need to instruct our patients
to avoid injecting into the identified areas of lipohypertrophy.
Because insulin injected into lipo was not all absorbed, the
patient injecting into healthy tissue must be counseled
regarding their risk for hypoglycemia. Patients typically
require a reduction in their insulin dose. Doses will vary
depending on the individual patient and the extent of their
lipohypertrophy, but a 20% insulin reduction is a good
starting point and some patients may require even greater
decreases in insulin dosages. Review the signs and symptoms
of hypoglycemia with your patient, and the Rule of 15 (15
grams of glucose, and wait 15 minutes to retest). Ask your
patient to check blood glucose values more frequently. If
they do not have a medical identification, provide them with a
list of resources to obtain one.

As per the recommendations of the Mayo Clinic Proceedings
(2016) shorter needle lengths are recommended. This should be
a 4mm pen needle or a 6 mm syringe. Not only are
shorter needles more comfortable and less intimidating, they
also decrease the frequency of unintended intramuscular
injections. Patients should also be instructed to ALWAYS use
a new needle for each injection. Reusing needles is highly
associated with lipohypertrophy (Frid, 2016). The risk of
lipohypertrophy also increases the more frequently the same
needle is used, up to an 85% increase when a needle is used 6
or more times (Blanco, 2013).

For many years diabetes educators have told patients to
rotate injection sites, but rarely have we given them a rotation
map or specific instructions in how to do this. When using
the abdomen for example, it is recommended to divide the
abdomen into quadrants with the umbilicus at the center.
Use one quadrant for a week, injecting a finger’s width away
from the previous injection, and then rotate to the next
quadrant. Another method is using an M or W pattern for the
injections in a single area before moving to another area.

Lipohypertrophy usually regresses when injections into the
affected area have ceased. Explain to patients that this process
takes a minimum of 2 to 3 months, but frequently longer.

In conclusion, our mission is: SUSPECT-DETECT-
PROTECT. Lipohypertrophy is a significant, and largely
unrecognized, clinical problem which contributes to erratic
blood glucose control, hypoglycemia and poor insulin
absorption. As health care providers and educators we have the
opportunity to provide our patient with education and greater
opportunities to avoid this complication of injection therapy.

References:
Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence
and risk factors of lipohypertrophy in insulin-injecting patients
Drake MT, & Smith SA. Optimizing insulin delivery in patients
with diabetes mellitus: still room for improvement. In Mayo
Famulla S, Hovelmann U, Fischer A, Coester, H. V., Hermanski, L.,
Kalthauer, M., ... & Hirsch, L. Insulin injection into
lipohypertrophic tissue: blunted and more variable insulin
absorption and action, and impaired post-prandial glucose
injection technique questionnaire study: injecting complications
and the role of the professional. In Mayo Clinic Proceedings,
Frid A,H, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, ... &
Kalra S. New insulin delivery recommendations. In Mayo Clinic
Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, ... &
Kalra S. New insulin delivery recommendations. In Mayo Clinic
Lipohypertrophy-Injections and lumpy skin.
Available at: [Accessed August 4, 2017].
https://www.diabetes.co.uk/conditions/lipohypertrophy.html

LIMITED SPECIAL OFFER

Healthy Moms - Health Families
Exercise Videos

Bundle 1 Office Copy and 5 Patient Copies for $20
Save $20 off the Reg price of $40
To take advantage order online, by mail, by emailing
ssep1@verizon or calling 800.732.2387 &
mention “SS Exercise Video Special”
GUIDELINES-AT-A GLANCE (Quick references)

#1023 - $60 - Complete Set of 3-SAVE $15/set
#1101 - $55/y - Individual Membership
#1102 - $125 yr - Organizational Membership (3 members in 1 facility)

SSEP CD Teaching PowerPoint Presentations

#1301 - SSEP SELF-STUDY SERIES CE COURSES Available Online UPDATED: 2016
Includes Guidelines at a Glance for GDM 2013; Current ADA Recommendations & Sweet Success Guidelines for Care 2015

- 01 - Preconception/Conception
- 02 - Medical Nutrition Therapy
- 03 - Screening & Dx GDM
- 04 - Self-monitoring Blood Glucose
- 05 - Medication Management
- 06 - Hypoglycemia
- 07 - Maternal/Fetal Assessment
- 08 - Intrapartum and Delivery
- 09 - PostPartum/Breastfeeding
- 10 - Neonatal Care
- 11 - Exercise

FREE: Guidelines at-a-Glance - Join & apply discount to this order! No tax or S/H for this item

SSEP CD Teaching PowerPoint Presentations

#1501 - $25 - NEW - 2016 - ADA Recommendations Tests for Screening and Diagnosing Diabetes during Pregnancy and Postpartum 36 slides-ADA & Sweet Success recommendations for testing. Ideal for in-services and new personnel.

#1601-04: Average (5th - 6th grade) reading level.

Enroll for Free Quarterly SSEP Newsletter
Send email address to ssep1@verizon.net

For more information email ssep1@verizon.net
www.sweetsuccessexpress.com

SSEP ORDER FORM

NAME______________________________________CIRCLE - MD RN/C RD/DRT NP MSW OTHER
ADDRESS______________________________________STATE________ZIP______________
PHONE______________FAX_______________________
EMAIL____________________ORDER DATE____________________

Item# Qty Description Price Each Times Qty Final Cost

ORDER TOTAL - DISCOUNTS ALLOWED
(Not includes S/H or Tax)

15% - SSEP Associate Programs Ship/handling [$5 up to $50]
10% - SSEP Individual/Organizational Members & CA Affiliate Programs ($12 orders $50-$200)
Affiliate/Individual Member ($20 orders $200-$500)

TOTAL

Method of PAYMENT

Check _____ Visa_______ MC_______ Disc_______ JCB_______
Card #_________________________ Exp. Date __________

Print name on card__________________________
Billing Address of Card if different from mailing address ________________________________

Checks Payable to: SSEP
Mail to: SSEP/PEC PO Box 7447 Chico, CA 95927-7447
Fax Credit Card orders at:530-343-3405 if > $500

Thank you!

For more information email ssep1@verizon.net
www.sweetsuccessexpress.org
The American College of Obstetricians and Gynecologists released a new Practice Bulletin on GDM, #180, in July. This bulletin replaces #137 from August 2013. The stated purpose of the updated bulletin recognizes: that “debate continues to surround the diagnosis and treatment of GDM despite several recent large-scale studies addressing these issues. The purposes of this document are the following: 1) provide a brief overview of the understanding of GDM, 2) review management guidelines that have been validated by appropriately conducted clinical research 3) identify gaps in current knowledge toward which future research can be directed.”

There was a recommendation from the U.S. Preventive Services Task Force in 2014 to screen all pregnant woman for GDM at or beyond 24 weeks gestation, and this is supported. The recommendation for earlier testing for undiagnosed Type II Diabetes is recommended based on BMI and risk factors adapted from the American Diabetes Association.

A complete review of the bulletin is advised for all practitioners caring for women in the peripartum period. Unfortunately, there continues to be a lack of national and expert consensus on diagnostic technique or cutoff values for diagnosis. The practice bulletin does stress the need for practitioners to establish criteria for their practice for consistency in communication and care, but does not state a preferred value. When making this decision, “factors such as community prevalence rates of GDM” should be considered. ACOG continues to recommend the two step approach to testing, recognizing that there are different cut-off standards for the 1 hour glucose challenge test, as well as for the cut-offs, and the number of abnormalities in the follow up 3-hour OGTT values for diagnosis of GDM.

Summary of Recommendations and Conclusions

Again a full review of this practice bulletin is recommended. Review of the entire summary is restricted here by space. Recommendations based on Level A evidence are two: 1) “Women in whom GDM is diagnosed should receive nutrition and exercise counseling, and when this fails to adequately control glucose levels, medication should be used for maternal and fetal health.” 2) “When pharmacologic treatment of GDM is indicated, insulin is considered the first-line treatment for diabetes in pregnancy.”

Some conclusions and recommendations based on Level B evidence:

“Glyburide treatment should not be recommended as a first-line pharmacologic treatment because, in most studies, it does not yield equivalent outcomes to insulin.”

“Women with GDM should be counseled regarding the risks and benefits of a scheduled cesarean delivery when the estimated fetal weight is 4,500 g or more.”

Level C recommendations and conclusions included:

“Once a woman with GDM begins nutrition therapy (dietary counseling), surveillance of blood glucose levels is required to confirm that glycemic control has been established.”

“The timing of delivery in women with GDM that is controlled with only diet and exercise (A1GDM) should not be before 39 weeks of gestation, unless otherwise indicated. In such women, expectant management up to 40 6/7 weeks of gestation in the setting of indicated antepartum testing is generally appropriate.”

“For women with GDM that is well controlled by medications (A2GDM), delivery is recommended at 39 0/7 to 39 6/7 weeks of gestation.”

---

**SSEP Membership PROGRAM**

**Benefits include:**
- FREE education product each year ($25.00+ value)
- Newsletter subscription
- Online/phone standard of care consults
- Conference registration discounts
- Discounts on education materials
- Monthly email updates
- Name entered in Summer Member Drawing (Prizes include free conference registrations, cash & gift certificates)
- Personalized membership card
- Membership fee tax deductible to the extent of the law
- Membership fee supports member services

**Cost:**
- Individual - $55/yr
- Organizational - $125/yr (Includes 3 members)

For more info visit [www.sweetsuccessexpress.org](http://www.sweetsuccessexpress.org) on the Products Page

This is your invitation to Join SSEP Membership

Please note: New Address and Phone for SSEP

SSEP, PO Box 7447, Chico, CA 95927, ssep1@verizon.net or Ph 800-732-2387